LUPIN Share Price Jumps 7.89% after Kotak Equities double upgrade to ‘add’
Lupin share price jumped over 8 percent on 04 July following a double upgrade from brokerage firm Kotak securities. Lupin share price closed at ₹1764.05 against its previous close of ₹1630.80. Brokerage establishment Kotak Securities has double upgraded Lupin stock to an ‘add’ from ‘sell’.
Lupin is a Mumbai based pharmaceutical company. Lupin has largest generic pharmaceutical companies by revenue globally. Company have wide range of products in paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.
Kotak believes that Lupin has a bunch of products lined up, which will insure a limited earnings dip in FY27 after a strong FY26 despite incinerating in a sharp decline in Albuterol deals over the coming couple of times.
Kotak expects Lupin’s robust US deals line to continue amid a stable US generics pricing terrain, despite declines in Albuterol and Suprep in FY25. Albuterol is used to treat or prevent bronchospasm in patients with asthma, bronchitis and Suprep is used to clean out your colon before a colonoscopy. Indeed though Spiriva and Albuterol, will still remain critical contributors to Lupin’s earnings in FY25 and FY26, the brokerage feels it’ll be Myrbetriq and Tolvaptan, that will make the coming financial remarkable for the drugmaker.
